Literature DB >> 3042210

Tolerance of engrafted donor T cells following bone marrow transplantation for severe combined immunodeficiency.

C A Keever1, N Flomenberg, J Brochstein, M Sullivan, N H Collins, J Burns, B Dupont, R J O'Reilly.   

Abstract

Patients transplanted for the treatment of severe combined immunodeficiency (SCID) frequently develop a unique state of split lymphoid chimerism. Such patients have T cells of donor origin, and non-T cells which are predominantly or exclusively of host origin. We have studied the reactivity of engrafted donor T cells to host and/or donor antigens in 12 patients transplanted for SCID, focusing on the characteristics of the tolerance to host and/or donor MHC antigens observed in nine of these patients who were recipients of T-cell-depleted, haploidentical parental bone marrow. In both proliferative and cytolytic assays, engrafted, donor-derived T cells were shown to be selectively nonreactive to histoincompatible host cells. This tolerance could not be ascribed to cells with suppressive activity in the engrafted T-cell population. T cells from a subset of patients, however, exhibited proliferative but not cytolytic reactivity to donor peripheral blood mononuclear cells. The responding cells were shown to be donor-derived CD3+ cells and were predominantly reactive to B-cell fractions from the donor. Two patients who received transplants from each parent in sequence engrafted T cells from one parent and had non-T cells of host, paternal, and maternal origin. The engrafted T cells proliferated weakly to B cells from the other parent, but were tolerant in cytolytic assays. Donor anti-donor reactivity was seen only in haploidentical split chimeras who had not been treated with cytotoxic drugs prior to T-cell engraftment. This proliferative reactivity toward donor may be due to an absence of donor derived Ia+ antigen presenting cells resident in the thymus of SCID patients at the time when the T-cell repertoire is being shaped.

Entities:  

Mesh:

Year:  1988        PMID: 3042210     DOI: 10.1016/0090-1229(88)90020-7

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  6 in total

1.  Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacement.

Authors:  Agnieszka Czechowicz; Irving L Weissman
Journal:  Hematol Oncol Clin North Am       Date:  2011-02       Impact factor: 3.722

Review 2.  Purified hematopoietic stem cell transplantation: the next generation of blood and immune replacement.

Authors:  Agnieszka Czechowicz; Irving L Weissman
Journal:  Immunol Allergy Clin North Am       Date:  2010-05       Impact factor: 3.479

3.  Anti-tetanus toxoid antibody production after mismatched T cell-depleted bone marrow transplantation.

Authors:  M Benkerrou; D W Wara; M Elder; Y Dror; A Merino; B W Colombe; M Garovoy; M J Cowan
Journal:  J Clin Immunol       Date:  1994-03       Impact factor: 8.317

4.  Chimerism and tolerance to host and donor in severe combined immunodeficiencies transplanted with fetal liver stem cells.

Authors:  R Bacchetta; B A Vandekerckhove; J L Touraine; M Bigler; S Martino; L Gebuhrer; J E de Vries; H Spits; M G Roncarolo
Journal:  J Clin Invest       Date:  1993-03       Impact factor: 14.808

Review 5.  Space-time considerations for hematopoietic stem cell transplantation.

Authors:  Deepta Bhattacharya; Lauren I Richie Ehrlich; Irving L Weissman
Journal:  Eur J Immunol       Date:  2008-08       Impact factor: 5.532

6.  High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells.

Authors:  R Bacchetta; M Bigler; J L Touraine; R Parkman; P A Tovo; J Abrams; R de Waal Malefyt; J E de Vries; M G Roncarolo
Journal:  J Exp Med       Date:  1994-02-01       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.